Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

AIM: To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS: This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:World J Gastrointest Oncol
Päätekijät: Chung, Moon Jae, Kang, Huapyong, Kim, Ho Gak, Hyun, Jong Jin, Lee, Jun Kyu, Lee, Kwang Hyuck, Noh, Myung Hwan, Kang, Dae Hwan, Lee, Sang Hyub, Bang, Seungmin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Baishideng Publishing Group Inc 2018
Aiheet:
Clinical Trials Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6304301/
https://ncbi.nlm.nih.gov/pubmed/30595804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.505
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia